Are Pharmas Doomed? Fire Those Blockbuster Peddlers and Embrace PGx, Urges POPI Head | GenomeWeb

Drug makers are in a world of hurt, and there’s little they can do about it — unless they embrace pharmacogenomics, according to the co-director of MIT’s Program on the Pharmaceutical Industry.

Despite huge growth in R&D outlays — pharmas collectively spent more than $45 billion on drug discovery and development in 2001 compared with $35 billion in 1985 — drug makers successfully brought to market fewer than 30 candidates two years ago compared to more than 60 in 1985, according to POPI.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.